Osteochondral lesions are a common clinical problem and their management has been historically challenging. Mesenchymal stem cells have the potential to differentiate into chondrocytes and thus restore hyaline cartilage to the defect, theoretically improving clincal outcomes in these patients. They can also be harvested with minimal donor site morbidity.
Purpose:
To assess the clinical and functional outcomes of mesenchymal stem cell implantation to treat isolated osteochondral defects of the knee. A secondary purpose is to assess the quality of the current available evidence as well as the radiological and histological outcomes. We also reviewed the cellular preparation and operative techniques for implantation.
Study Design:
Systematic review.
Methods:
A comprehensive literature search of 4 databases was carried out: CINAHL, Embase, MEDLINE, and PubMed. We searched for clinical studies reporting the outcomes on a minimum of 5 patients with at least 12 months of follow-up. Clinical, radiological, and histological outcomes were recorded. We also recorded demographics, stem cell source, culture technique, and operative technique. Methodological quality of each study was assessed using the modified Coleman methodology score, and risk of bias for the randomized controlled studies was assessed using the Cochrane Collaboration tool.
Results:
Seventeen studies were found, encompassing 367 patients. The mean patient age was 35.1 years. Bone marrow was the most common source of stem cells utilized. Mesenchymal stem cell therapy consistently demonstrated good short- to medium-term outcomes in the studies reviewed with no serious adverse events being recorded. There was significant heterogeneity in cell harvesting and preparation as well as in the reporting of outcomes.
Conclusion:
Mesenchymal stem cells demonstrated a clinically relevant improvement in outcomes in patients with osteochondral defects of the knee. More research is needed to establish an optimal treatment protocol, long-term outcomes, and superiority over other therapies.
AkgunIUnluMCErdalOA, et al. Matrix-induced autologous mesenchymal stem cell implantation versus matrix-induced autologous chondrocyte implantation in the treatment of chondral defects of the knee: a 2-year randomized study. Arch Orthop Trauma Surg. 2015;135(2):251-263.
2.
AlfordJWColeBJ. Cartilage restoration, part 1: basic science, historical perspective, patient evaluation, and treatment options. Am J Sports Med. 2005;33(2):295-306.
3.
AmariglioNHirshbergAScheithauerBW, et al. Donor-derived brain tumor following neural stem cell transplantation in an ataxia telangiectasia patient. PLoS Med. 2009;6(2):e1000029.
4.
AndersonAFIrrgangJJKocherMSMannBJHarrastJJ. The International Knee Documentation Committee subjective knee evaluation form: normative data. Am J Sports Med. 2006;34(1):128-135.
5.
AndersonJALittleDTothAP, et al. Stem cell therapies for knee cartilage repair: the current status of preclinical and clinical studies. Am J Sports Med. 2014;42(9):2253-2261.
6.
ÅrøenALøkenSHeirS, et al. Articular cartilage lesions in 993 consecutive knee arthroscopies. Am J Sports Med. 2004;32(1):211-215.
7.
AwadMEHusseinKAHelwaI, et al. Meta-analysis and evidence base for the efficacy of autologous bone marrow mesenchymal stem cells in knee cartilage repair: methodological guidelines and quality assessment. Stem Cells Int. 2019;2019:3826054.
8.
BiebackKHeckerAKocaömerA, et al. Human alternatives to fetal bovine serum for the expansion of mesenchymal stromal cells from bone marrow. Stem Cells. 2009;27(9):2331-2341.
9.
BudaRVanniniFCavalloM, et al. One-step arthroscopic technique for the treatment of osteochondral lesions of the knee with bone-marrow-derived cells: three years results. Musculoskelet Surg. 2013;97(2):145-151.
CentenoCJBusseDKisidayJKeohanCFreemanMKarliD. Increased knee cartilage volume in degenerative joint disease using percutaneously implanted, autologous mesenchymal stem cells. Pain Physician. 2008;11(3):343-353.
12.
CurlWWKromeJGordonESRushingJSmithBPPoehlingGG. Cartilage injuries: a review of 31,516 knee arthroscopies. Arthroscopy. 1997;13(4):456-460.
13.
de GirolamoLSchönhuberHViganòM, et al. Autologous matrix-induced chondrogenesis (AMIC) and AMIC enhanced by autologous concentrated bone marrow aspirate (BMAC) allow for stable clinical and functional improvements at up to 9 years follow-up: results from a randomized controlled study. J Clin Med. 2019;8(3):392.
14.
de WindtTSVonkLASlaper-CortenbachICMNizakRvan RijenMHPSarisDBF. Allogeneic MSCs and recycled autologous chondrons mixed in a one-stage cartilage cell transplantion: a first-in-man trial in 35 patients. Stem Cells. 2017;35(8):1984-1993.
15.
Del BuonoAVolpinAMaffulliN. Minimally invasive versus open surgery for acute Achilles tendon rupture: a systematic review. Br Med Bull. 2013;109(1):45-54.
16.
DominiciMLe BlancKMuellerI, et al. Minimal criteria for defining multipotent mesenchymal stromal cells: the International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315-317.
FernandesTLKimuraHAPinheiroCCG, et al. Human synovial MSC good manufacturing practices for articular cartilage regeneration. Tissue Eng Part C Methods. 2018;24(12):709-716.
19.
FrehnerFBenthienJP. Microfracture: state of the art in cartilage surgery?Cartilage. 2017;9(4):339-345.
20.
GirãoAFSemitelaÂRamalhoGCompletoAMarquesPAAP. Mimicking nature: fabrication of 3D anisotropic electrospun polycaprolactone scaffolds for cartilage tissue engineering applications. Compos Part B Eng. 2018;154:99-107.
21.
GobbiAWhyteGP. Long-term clinical outcomes of one-stage cartilage repair in the knee with hyaluronic acid–based scaffold embedded with mesenchymal stem cells sourced from bone marrow aspirate concentrate. Am J Sports Med. 2019;47(7):1621-1628.
22.
HaC-WParkY-BKimSHLeeH-J. Intra-articular mesenchymal stem cells in osteoarthritis of the knee: a systematic review of clinical outcomes and evidence of cartilage repair. Arthroscopy. 2019;35(1):277-288.e2.
23.
HaleemAMEl SingergyAASabryD, et al. The clinical use of human culture–expanded autologous bone marrow mesenchymal stem cells transplanted on platelet-rich fibrin glue in the treatment of articular cartilage defects: a pilot study and preliminary results. Cartilage. 2010;1(4):253-261.
24.
HanYLiXZhangYHanYChangFDingJ. Mesenchymal stem cells for regenerative medicine. Cells. 2019;8(8):886.
25.
HashimotoYNishidaYTakahashiS, et al. Transplantation of autologous bone marrow–derived mesenchymal stem cells under arthroscopic surgery with microfracture versus microfracture alone for articular cartilage lesions in the knee: a multicenter prospective randomized control clinical trial. Regen Ther. 2019;11:106-113.
26.
HauseRAEtesholaE. Rationale for using direct bone marrow aspirate as a proliferant for regenerative injection therapy (prolotherapy). Open Stem Cell J. 2013;4:7-14.
27.
HjelleKSolheimEStrandTMuriRBrittbergM. Articular cartilage defects in 1,000 knee arthroscopies. Arthroscopy. 2002;18(7):730-734.
28.
IyerSSRojasM. Anti-inflammatory effects of mesenchymal stem cells: novel concept for future therapies. Expert Opin Biol Ther. 2008;8(5):569-581.
29.
KameiNOchiMAdachiN, et al. The safety and efficacy of magnetic targeting using autologous mesenchymal stem cells for cartilage repair. Knee Surg Sports Traumatol Arthrosc. 2018;26(12):3626-3635.
30.
KimILeeSKYoonJIKimDEKimMHaH. Fibrin glue improves the therapeutic effect of MSCs by sustaining survival and paracrine function. Tissue Eng Part A. 2013;19(21-22):2373-2381.
31.
KimSHHaC-WParkY-BNamELeeJ-ELeeH-J. Intra-articular injection of mesenchymal stem cells for clinical outcomes and cartilage repair in osteoarthritis of the knee: a meta-analysis of randomized controlled trials. Arch Orthop Trauma Surg. 2019;139(7):971-980.
32.
KohY-GKwonO-RKimY-SChoiY-JTakD-H. Adipose-derived mesenchymal stem cells with microfracture versus microfracture alone: 2-year follow-up of a prospective randomized trial. Arthroscopy. 2016;32(1):97-109.
33.
KraeutlerMJBelkJWPurcellJMMcCartyEC. Microfracture versus autologous chondrocyte implantation for articular cartilage lesions in the knee: a systematic review of 5-year outcomes. Am J Sports Med. 2017;46(4):995-999.
34.
KyriakidisTIosifidisMMichalopoulosEMelasIStavropoulos-GiokasCVerdonkR. Good mid-term outcomes after adipose-derived culture-expanded mesenchymal stem cells implantation in knee focal cartilage defects. Knee Surg Sports Traumatol Arthrosc. 2020;28(2):502-508.
35.
LinPPWangYLozanoG. Mesenchymal stem cells and the origin of Ewing’s sarcoma. Sarcoma. 2011;2011:276463.
36.
LundquistRDziegielMHÅgrenMS. Bioactivity and stability of endogenous fibrogenic factors in platelet-rich fibrin. Wound Repair Regen. 2008;16(3):356-363.
37.
MackayAMBeckSCMurphyJMBarryFPChichesterCOPittengerMF. Chondrogenic differentiation of cultured human mesenchymal stem cells from marrow. Tissue Eng. 1998;4(4):415-428.
38.
MallNAHarrisJDColeBJ. Clinical evaluation and preoperative planning of articular cartilage lesions of the knee. J Am Acad Orthop Surg. 2015;23(10):633-640.
39.
MarlovitsSStriessnigGResingerCT, et al. Definition of pertinent parameters for the evaluation of articular cartilage repair tissue with high-resolution magnetic resonance imaging. Eur J Radiol. 2004;52(3):310-319.
40.
MistryHConnockMPinkJ, et al. Autologous chondrocyte implantation in the knee: systematic review and economic evaluation. Health Technol Assess. 2017;21(6):1-294.
41.
MonckebergJERafolsCApablazaFGerhardPRosalesJ. Intra-articular administration of peripheral blood stem cells with platelet-rich plasma regenerated articular cartilage and improved clinical outcomes for knee chondral lesions. Knee. 2019;26(4):824-831.
42.
NejadnikHHuiJHFeng ChoongEPTaiB-CLeeEH. Autologous bone marrow–derived mesenchymal stem cells versus autologous chondrocyte implantation: an observational cohort study. Am J Sports Med. 2010;38(6):1110-1116.
43.
OussedikSTsitskarisKParkerD. Treatment of articular cartilage lesions of the knee by microfracture or autologous chondrocyte implantation: a systematic review. Arthroscopy. 2015;31(4):732-744.
44.
PaschosNKSennettML. Update on mesenchymal stem cell therapies for cartilage disorders. World J Orthop. 2017;8(12):853-860.
45.
PeiMHeFBoyceBMKishVL. Repair of full-thickness femoral condyle cartilage defects using allogeneic synovial cell-engineered tissue constructs. Osteoarthritis Cartilage. 2009;17(6):714-722.
46.
PetersonLVasiliadisHSBrittbergMLindahlA. Autologous chondrocyte implantation: a long-term follow-up. Am J Sports Med. 2010;38(6):1117-1124.
47.
PipinoGRisitanoSAlvianoF, et al. Microfractures and hydrogel scaffolds in the treatment of osteochondral knee defects: a clinical and histological evaluation. J Clin Orthop Trauma. 2019;10(1):67-75.
SakaguchiYSekiyaIYagishitaKMunetaT. Comparison of human stem cells derived from various mesenchymal tissues: superiority of synovium as a cell source. Arthritis Rheum. 2005;52(8):2521-2529.
50.
SawK-YAnzASiew-Yoke JeeC, et al. Articular cartilage regeneration with autologous peripheral blood stem cells versus hyaluronic acid: a randomized controlled trial. Arthroscopy. 2013;29(4):684-694.
51.
SekiyaIMunetaTHorieMKogaH. Arthroscopic transplantation of synovial stem cells improves clinical outcomes in knees with cartilage defects. Clin Orthop Relat Res. 2015;473(7):2316-2326.
52.
ShapiroSAKazmerchakSEHeckmanMGZubairACO’ConnorMI. A prospective, single-blind, placebo-controlled trial of bone marrow aspirate concentrate for knee osteoarthritis. Am J Sports Med. 2016;45(1):82-90.
53.
ShimomuraKYasuiYKoizumiK, et al. First-in-human pilot study of implantation of a scaffold-free tissue-engineered construct generated from autologous synovial mesenchymal stem cells for repair of knee chondral lesions. Am J Sports Med. 2018;46(10):2384-2393.
54.
ShirasawaSSekiyaISakaguchiYYagishitaKIchinoseSMunetaT. In vitro chondrogenesis of human synovium-derived mesenchymal stem cells: optimal condition and comparison with bone marrow–derived cells. J Cell Biochem. 2006;97(1):84-97.
55.
SkowrońskiJRutkaM. Osteochondral lesions of the knee reconstructed with mesenchymal stem cells—results. Ortop Traumatol Rehabil. 2013;15(3):195-204.
56.
SmithBSigalIRGrandeDA. Immunology and cartilage regeneration. Immunol Res. 2015;63(1):181-186.
57.
SterneJACSavovićJPageMJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.
58.
TeoAQAWongKLShenL, et al. Equivalent 10-year outcomes after implantation of autologous bone marrow–derived mesenchymal stem cells versus autologous chondrocyte implantation for chondral defects of the knee. Am J Sports Med. 2019;47(12):2881-2887.
59.
WakitaniSImotoKYamamotoTSaitoMMurataNYonedaM. Human autologous culture expanded bone marrow mesenchymal cell transplantation for repair of cartilage defects in osteoarthritic knees. Osteoarthritis Cartilage. 2002;10(3):199-206.
60.
WakitaniSOkabeTHoribeS, et al. Safety of autologous bone marrow–derived mesenchymal stem cell transplantation for cartilage repair in 41 patients with 45 joints followed for up to 11 years and 5 months. J Tissue Eng Regen Med. 2011;5(2):146-150.
61.
WongKLLeeKBLTaiBCLawPLeeEHHuiJHP. Injectable cultured bone marrow–derived mesenchymal stem cells in varus knees with cartilage defects undergoing high tibial osteotomy: a prospective, randomized controlled clinical trial with 2 years’ follow-up. Arthroscopy. 2013;29(12):2020-2028.
62.
YooJUBarthelTSNishimuraK, et al. The chondrogenic potential of human bone-marrow-derived mesenchymal progenitor cells. J Bone Joint Surg Am. 1998;80(12):1745-1757.
